Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Potential Factors Influencing Repeated SARS Outbreaks in China.

Sun Z, Thilakavathy K, Kumar SS, He G, Liu SV.

Int J Environ Res Public Health. 2020 Mar 3;17(5). pii: E1633. doi: 10.3390/ijerph17051633. Review.

2.

Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001.

Paz-Ares L, Doebele RC, Farago AF, Liu SV, Chawla SP, Tosi D, Blakely CM, Krauss JC, Sigal D, Bazhenova L, John T, Besse B, Wolf J, Seto T, Chow-Maneval E, Ye C, Simmons B, Demetri GD.

Ann Oncol. 2019 Apr;30 Suppl 2:ii48-ii49. doi: 10.1093/annonc/mdz063.011. No abstract available.

3.

Enhancing life cycle chemical exposure assessment through ontology modeling.

Meyer DE, Bailin SC, Vallero D, Egeghy PP, Liu SV, Cohen Hubal EA.

Sci Total Environ. 2020 Apr 10;712:136263. doi: 10.1016/j.scitotenv.2019.136263. Epub 2019 Dec 27.

PMID:
32050401
4.

Dashing Decades of Defeat: Long Anticipated Advances in the First-line Treatment of Extensive-Stage Small Cell Lung Cancer.

Armstrong SA, Liu SV.

Curr Oncol Rep. 2020 Feb 7;22(2):20. doi: 10.1007/s11912-020-0887-y. Review.

PMID:
32034529
5.

Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial.

Mansfield AS, Każarnowicz A, Karaseva N, Sánchez A, De Boer R, Andric Z, Reck M, Atagi S, Lee JS, Garassino M, Liu SV, Horn L, Wen X, Quach C, Yu W, Kabbinavar F, Lam S, Morris S, Califano R.

Ann Oncol. 2020 Feb;31(2):310-317. doi: 10.1016/j.annonc.2019.10.021. Epub 2019 Dec 9.

6.

Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection.

Shah NJ, Al-Shbool G, Blackburn M, Cook M, Belouali A, Liu SV, Madhavan S, He AR, Atkins MB, Gibney GT, Kim C.

J Immunother Cancer. 2019 Dec 17;7(1):353. doi: 10.1186/s40425-019-0771-1.

7.

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.

Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators.

Lancet Oncol. 2020 Feb;21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11. Erratum in: Lancet Oncol. 2020 Feb;21(2):e70.

PMID:
31838007
8.

First-line EGFR TKI therapy in non-small-cell lung cancer: looking back before leaping forward.

Kim C, Liu SV.

Ann Oncol. 2019 Dec 1;30(12):1852-1855. doi: 10.1093/annonc/mdz415. No abstract available.

PMID:
31613313
9.

Combining immunotherapy and epidermal growth factor receptor kinase inhibitors: worth the risk?

Latif H, Liu SV.

Ann Transl Med. 2019 Jul;7(Suppl 3):S76. doi: 10.21037/atm.2019.03.6. No abstract available.

10.

Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration.

Mountzios G, Remon J, Novello S, Blais N, Califano R, Cufer T, Dingemans AM, Liu SV, Peled N, Pennell NA, Reck M, Rolfo C, Tan D, Vansteenkiste J, West H, Besse B.

Ann Oncol. 2019 Nov 1;30(11):1686-1688. doi: 10.1093/annonc/mdz295. No abstract available.

PMID:
31504132
11.

A meta-analysis of selected near-road air pollutants based on concentration decay rates.

Liu SV, Chen FL, Xue J.

Heliyon. 2019 Aug 23;5(8):e02236. doi: 10.1016/j.heliyon.2019.e02236. eCollection 2019 Aug.

12.

Linear IgA Disease of the Gingiva Following Nivolumab Therapy.

Jonna S, Neiders M, Lakshmanan S, Khan A, DeKlotz T, Lanasa D, Gibney GT, Liu SV.

J Immunother. 2019 Nov/Dec;42(9):345-347. doi: 10.1097/CJI.0000000000000288.

PMID:
31246639
13.

Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC.

Antonia SJ, Balmanoukian A, Brahmer J, Ou SI, Hellmann MD, Kim SW, Ahn MJ, Kim DW, Gutierrez M, Liu SV, Schöffski P, Jäger D, Jamal R, Jerusalem G, Lutzky J, Nemunaitis J, Calabrò L, Weiss J, Gadgeel S, Bhosle J, Ascierto PA, Rebelatto MC, Narwal R, Liang M, Xiao F, Antal J, Abdullah S, Angra N, Gupta AK, Khleif SN, Segal NH.

J Thorac Oncol. 2019 Oct;14(10):1794-1806. doi: 10.1016/j.jtho.2019.06.010. Epub 2019 Jun 20.

14.

Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Partially Realized Potential.

Armstrong SA, Liu SV.

Adv Ther. 2019 Aug;36(8):1826-1832. doi: 10.1007/s12325-019-01008-2. Epub 2019 Jun 17. Review.

15.

A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma.

McMichael EL, Benner B, Atwal LS, Courtney NB, Mo X, Davis ME, Campbell AR, Duggan MC, Williams K, Martin K, Levine K, Olaverria Salavaggione GN, Noel T, Ganju A, Uppati S, Paul B, Olencki T, Teknos TN, Savvides P, Tridandapani S, Byrd JC, Caligiuri MA, Liu SV, Carson WE 3rd.

Clin Cancer Res. 2019 Aug 15;25(16):4955-4965. doi: 10.1158/1078-0432.CCR-18-2108. Epub 2019 May 29.

PMID:
31142501
16.

Detection of NRG1 Gene Fusions in Solid Tumors.

Jonna S, Feldman RA, Swensen J, Gatalica Z, Korn WM, Borghaei H, Ma PC, Nieva JJ, Spira AI, Vanderwalde AM, Wozniak AJ, Kim ES, Liu SV.

Clin Cancer Res. 2019 Aug 15;25(16):4966-4972. doi: 10.1158/1078-0432.CCR-19-0160. Epub 2019 Apr 15.

PMID:
30988082
17.

Atezolizumab plus Chemotherapy in Small-Cell Lung Cancer. Reply.

Horn L, Liu SV.

N Engl J Med. 2019 Feb 28;380(9):889-890. doi: 10.1056/NEJMc1900123. No abstract available.

PMID:
30811922
18.

ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events.

Ng TL, Smith DE, Mushtaq R, Patil T, Dimou A, Yang S, Liu Q, Li X, Zhou C, Jones RT, Tu MM, Yan F, Bowman IA, Liu SV, Newkirk S, Bauml J, Doebele RC, Aisner DL, Gao D, Ren S, Camidge DR.

J Thorac Oncol. 2019 Apr;14(4):596-605. doi: 10.1016/j.jtho.2018.12.001. Epub 2018 Dec 10.

PMID:
30543838
19.

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.

Drilon A, Fu S, Patel MR, Fakih M, Wang D, Olszanski AJ, Morgensztern D, Liu SV, Cho BC, Bazhenova L, Rodriguez CP, Doebele RC, Wozniak A, Reckamp KL, Seery T, Nikolinakos P, Hu Z, Oliver JW, Trone D, McArthur K, Patel R, Multani PS, Ahn MJ.

Cancer Discov. 2019 Mar;9(3):384-395. doi: 10.1158/2159-8290.CD-18-0839. Epub 2018 Nov 28.

20.

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.

Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group.

N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25.

PMID:
30280641
21.
22.

Short-term changes in added sugar consumption by adolescents reflected in the carbon isotope ratio of fingerstick blood.

Liu SV, Moore LB, Halliday TM, Jahren AH, Savla J, Hedrick VE, Marinik EL, Davy BM.

Nutr Health. 2018 Sep 20:260106018799522. doi: 10.1177/0260106018799522. [Epub ahead of print]

PMID:
30231801
23.

A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors.

Liu SV, Groshen SG, Kelly K, Reckamp KL, Belani C, Synold TW, Goldkorn A, Gitlitz BJ, Cristea MC, Gong IY, Semrad TJ, Xu Y, Xu T, Koczywas M, Gandara DR, Newman EM.

Cancer Chemother Pharmacol. 2018 Oct;82(4):723-732. doi: 10.1007/s00280-018-3672-y. Epub 2018 Aug 20.

24.

Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer.

Kim IK, McCutcheon JN, Rao G, Liu SV, Pommier Y, Skrzypski M, Zhang YW, Giaccone G.

Oncogene. 2019 Jan;38(2):180-193. doi: 10.1038/s41388-018-0429-3. Epub 2018 Aug 9.

PMID:
30093630
25.

Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.

Liu SV, Camidge DR, Gettinger SN, Giaccone G, Heist RS, Hodi FS, Ready NE, Zhang W, Wallin J, Funke R, Waterkamp D, Foster P, Iizuka K, Powderly J.

Eur J Cancer. 2018 Sep;101:114-122. doi: 10.1016/j.ejca.2018.06.033. Epub 2018 Jul 24.

PMID:
30053670
26.
27.

Racial Disparities in the Molecular Landscape of Cancer.

Heath EI, Lynce F, Xiu J, Ellerbrock A, Reddy SK, Obeid E, Liu SV, Bollig-Fischer A, Separovic D, Vanderwalde A.

Anticancer Res. 2018 Apr;38(4):2235-2240.

28.

Buccal venom gland associates with increased of diversification rate in the fang blenny fish Meiacanthus (Blenniidae; Teleostei).

Liu SV, Frédérich B, Lavoué S, Chang J, Erdmann MV, Mahardika GN, Barber PH.

Mol Phylogenet Evol. 2018 Aug;125:138-146. doi: 10.1016/j.ympev.2018.03.027. Epub 2018 Mar 26.

29.

A Phase Ib/II Study of Ganetespib With Doxorubicin in Advanced Solid Tumors Including Relapsed-Refractory Small Cell Lung Cancer.

Subramaniam DS, Liu SV, Crawford J, Kramer J, Thompson J, Wang H, Giaccone G.

Front Oncol. 2018 Mar 12;8:64. doi: 10.3389/fonc.2018.00064. eCollection 2018.

30.

Role of IL-28B genetic variants in HCV-related liver disease severity in patients with different viral genotypes.

Huang CI, Huang CF, Yeh ML, Lin YH, Liang PC, Liu SV, Hsieh MH, Lin ZY, Chen SC, Huang JF, Chuang WL, Dai CY, Yu ML.

Medicine (Baltimore). 2018 Mar;97(10):e9782. doi: 10.1097/MD.0000000000009782.

31.

Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study.

Cohen RB, Delord JP, Doi T, Piha-Paul SA, Liu SV, Gilbert J, Algazi AP, Damian S, Hong RL, Le Tourneau C, Day D, Varga A, Elez E, Wallmark J, Saraf S, Thanigaimani P, Cheng J, Keam B.

Am J Clin Oncol. 2018 Feb 21. doi: 10.1097/COC.0000000000000429. [Epub ahead of print]

32.

Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study.

Giaccone G, Kim C, Thompson J, McGuire C, Kallakury B, Chahine JJ, Manning M, Mogg R, Blumenschein WM, Tan MT, Subramaniam DS, Liu SV, Kaplan IM, McCutcheon JN.

Lancet Oncol. 2018 Mar;19(3):347-355. doi: 10.1016/S1470-2045(18)30062-7. Epub 2018 Jan 26.

PMID:
29395863
33.
34.

Product review on the Anti-PD-L1 antibody atezolizumab.

Shah NJ, Kelly WJ, Liu SV, Choquette K, Spira A.

Hum Vaccin Immunother. 2018 Feb 1;14(2):269-276. doi: 10.1080/21645515.2017.1403694. Epub 2017 Dec 20.

35.

Urinary Excretion of Sodium, Nitrogen, and Sugar Amounts Are Valid Biomarkers of Dietary Sodium, Protein, and High Sugar Intake in Nonobese Adolescents.

Moore LB, Liu SV, Halliday TM, Neilson AP, Hedrick VE, Davy BM.

J Nutr. 2017 Dec;147(12):2364-2373. doi: 10.3945/jn.117.256875. Epub 2017 Sep 20.

36.

Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.

Cabanillas ME, de Souza JA, Geyer S, Wirth LJ, Menefee ME, Liu SV, Shah K, Wright J, Shah MH.

J Clin Oncol. 2017 Oct 10;35(29):3315-3321. doi: 10.1200/JCO.2017.73.0226. Epub 2017 Aug 17.

37.

Spatial genetic structure and body size divergence in endangered Gymnogobius isaza in ancient Lake Biwa.

Nakazawa T, Liu SV, Sakai Y, Araki KS, Tsai CH, Okuda N.

Mitochondrial DNA A DNA Mapp Seq Anal. 2018 Jul;29(5):756-764. doi: 10.1080/24701394.2017.1357708. Epub 2017 Jul 26.

PMID:
28745537
38.

A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer.

Yu SS, Athreya K, Liu SV, Schally AV, Tsao-Wei D, Groshen S, Quinn DI, Dorff TB, Xiong S, Engel J, Pinski J.

Clin Genitourin Cancer. 2017 Dec;15(6):742-749. doi: 10.1016/j.clgc.2017.06.002. Epub 2017 Jun 8.

PMID:
28668277
39.

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.

Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Shu X, Cheng JD, Haddad R.

J Clin Oncol. 2017 May 10;35(14):1542-1549. doi: 10.1200/JCO.2016.70.1524. Epub 2017 Mar 22.

40.

Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers.

Weinberg BA, Gowen K, Lee TK, Ou SI, Bristow R, Krill L, Almira-Suarez MI, Ali SM, Miller VA, Liu SV, Klempner SJ.

Oncologist. 2017 Feb;22(2):152-157. doi: 10.1634/theoncologist.2015-0511. Epub 2017 Feb 13.

41.

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG.

Cancer Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9.

42.

A new family of poecilostomatoid copepods (Strepidae fam. nov.) associated with the sun coral, Tubastraea coccinea Lesson, 1829 in Taiwan.

Cheng YR, Liu SV, Dai CF.

Zootaxa. 2016 Oct 11;4174(1):346-354. doi: 10.11646/zootaxa.4174.1.21.

PMID:
27811804
43.

Isoaspartylation appears to trigger small cell lung cancer-associated autoimmunity against neuronal protein ELAVL4.

Pulido MA, DerHartunian MK, Qin Z, Chung EM, Kang DS, Woodham AW, Tsou JA, Klooster R, Akbari O, Wang L, Kast WM, Liu SV, Verschuuren JJGM, Aswad DW, Laird-Offringa IA.

J Neuroimmunol. 2016 Oct 15;299:70-78. doi: 10.1016/j.jneuroim.2016.09.002. Epub 2016 Sep 3.

44.

Lung cancer: First-line immunotherapy in lung cancer - taking the first step.

Liu SV, Giaccone G.

Nat Rev Clin Oncol. 2016 Oct;13(10):595-6. doi: 10.1038/nrclinonc.2016.148. Epub 2016 Sep 13. No abstract available.

PMID:
27620712
45.

Novel approaches in cancer immunotherapy.

Subramaniam DS, Liu SV, Giaccone G.

Discov Med. 2016 Apr;21(116):267-74.

46.

Biodiversity management of organic farming enhances agricultural sustainability.

Liu H, Meng J, Bo W, Cheng D, Li Y, Guo L, Li C, Zheng Y, Liu M, Ning T, Wu G, Yu X, Feng S, Wuyun T, Li J, Li L, Zeng Y, Liu SV, Jiang G.

Sci Rep. 2016 Apr 1;6:23816. doi: 10.1038/srep23816.

47.

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).

Drilon A, Li G, Dogan S, Gounder M, Shen R, Arcila M, Wang L, Hyman DM, Hechtman J, Wei G, Cam NR, Christiansen J, Luo D, Maneval EC, Bauer T, Patel M, Liu SV, Ou SH, Farago A, Shaw A, Shoemaker RF, Lim J, Hornby Z, Multani P, Ladanyi M, Berger M, Katabi N, Ghossein R, Ho AL.

Ann Oncol. 2016 May;27(5):920-6. doi: 10.1093/annonc/mdw042. Epub 2016 Feb 15.

48.

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.

Farago AF, Le LP, Zheng Z, Muzikansky A, Drilon A, Patel M, Bauer TM, Liu SV, Ou SH, Jackman D, Costa DB, Multani PS, Li GG, Hornby Z, Chow-Maneval E, Luo D, Lim JE, Iafrate AJ, Shaw AT.

J Thorac Oncol. 2015 Dec;10(12):1670-4. doi: 10.1097/01.JTO.0000473485.38553.f0.

49.

Outpatient Autologous Stem Cell Transplantation for Patients With Myeloma.

Paul TM, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ, Tsai DE, Nasta SD, Loren A, Frey N, Perl A, Cohen AD, Weiss BM, Stadtmauer EA, Vogl DT.

Clin Lymphoma Myeloma Leuk. 2015 Sep;15(9):536-40. doi: 10.1016/j.clml.2015.05.006. Epub 2015 Jun 6.

PMID:
26141214
50.

Refining the treatment of NSCLC according to histological and molecular subtypes.

Thomas A, Liu SV, Subramaniam DS, Giaccone G.

Nat Rev Clin Oncol. 2015 Sep;12(9):511-26. doi: 10.1038/nrclinonc.2015.90. Epub 2015 May 12. Review.

PMID:
25963091

Supplemental Content

Support Center